Testing NaBen add-on to clozapine for tough schizophrenia symptoms
Part of Mental health clinical trials.
This trial tests whether adding NaBen (a supplement-like medicine) to clozapine can improve “residual” symptoms in adults with difficult-to-treat schizophrenia. The study also checks safety and the best dose, using a placebo (inactive pill) for comparison.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re 18 to 55 years old, and you can provide consent (or your legal representative can).
- You’ve been diagnosed with schizophrenia and it has been ongoing for at least 2 years.
- Your schizophrenia has not responded well to at least 2 different antipsychotic medicines, and you’ve had significant symptoms (or no good periods) recently.
- You’ve been taking clozapine for at least 6 months at a steady dose (200–900 mg/day), with no dose change for at least 3 months.
- At screening and start of the study, your symptom score (PANSS total) is at least 70, and you’re not recently worsening enough to be hospitalized.
- You have a reliable caregiver or support person to help with study visits and check-ins, and you’re not a danger to yourself or others.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a new medicine, NTX-253, to see how safe it is and how the body processes it. It is for healthy adults and adults with schizophrenia whose symptoms are stable on their current treatment.
This trial tests a new medicine, NBI-1117568, to see if it can help prevent a relapse of schizophrenia symptoms. It is for adults who have been stable on other antipsychotics and want to avoid returning to the hospital for a psychiatric stay.
This trial tests a new medication, evenamide, added to your current antipsychotic treatment. It looks to see if it can help people whose schizophrenia has not responded well to standard therapies.
This study tests an experimental drug (NBI-1117568) for people with schizophrenia who are currently in the hospital due to worsening symptoms. Participants stop their current antipsychotic and take the study drug to see if it can help control symptoms.
This study tests whether adding a supplement called sodium benzoate to your current antipsychotic medication can improve symptoms in schizophrenia that hasn't responded well to standard treatments. Researchers will measure brain chemistry changes and symptom improvement over time.
This trial tests a combination of an NMDA-targeting medicine and an anti-inflammatory treatment for people with schizophrenia that has not responded well to several standard treatments, including clozapine. If you qualify, the goal is to see whether this combination improves symptoms more than usual care.
Hear when a new Refractory Schizophrenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.